POINT Biopharma focuses on precision radioligand therapy and radiopharmaceuticals to treat a variety of cancers. The company is advancing a pipeline that includes PNT2002, a 177Lu‑PSMA radiotherapeutic now in a Phase 3 trial for metastatic castrate‑resistant prostate cancer. POINT says it will disclose additional programs in the coming months and is pursuing further pipeline expansion. Proceeds from its financing are intended to strengthen development and commercialization efforts and to expand manufacturing capabilities. POINT has purchased and built out a 77,000 sqft radioligand manufacturing facility in Indianapolis, Indiana to support its plans. Leadership emphasizes global commercialization experience and a mission to expand access to radioligand treatments.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2020